Item 8.01. Other Events
On October 15, 2009, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa) in treatment naive patients diagnosed with Gaucher disease. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press release dated October 15, 2009.

---